Exelixis Analyst Price Targets - Benzinga

Exelixis Inc

EXELNASDAQ

Trade with Public

Trade with Public

$59.82

-0.04-0.07%

Dern. MÀJ: Oct 12, 4:25 PM

$59.63

-0.23-0.38%

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

Exelixis Analyst Price Targets - Benzinga

Exelixis Analyst Price Targets

Wall Street analyst price targets and consensus rating for Exelixis (EXEL).

Price Target Range — 9 Quarters

Analyst Consensus — 17 Analysts

2S.Buy

8Buy

7Hold

Consensus RatingBuy# Analysts17Avg. Consensus PT$48Upside to Avg. PT-19.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 9, 2026	RBC Capital	Leonid Timashev	PT Raise	Sector Perform	$45→$51
Oct 8, 2026	RBC Capital	Leonid Timashev	PT Cut	Sector Perform	$46→$45
Oct 7, 2026	Truist Securities	Gregory Renza	PT Raise	Hold	$52→$54
Aug 19, 2026	BMO Capital	David Lebowitz	Initiate	Market Perform	$54
Aug 6, 2026	Truist Securities	Gregory Renza	PT Cut	Hold	$56→$52
Aug 6, 2026	Stifel	Stephen Willey	PT Raise	Hold	$47→$51
Jul 23, 2026	Morgan Stanley	Sean Laaman	PT Raise	Equal-Weight	$50→$53
Jul 14, 2026	Barclays	Etzer Darout	PT Raise	Equal-Weight	$45→$49
Jul 13, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Equal-Weight	$40→$49
Jul 7, 2026	RBC Capital	Leonid Timashev	PT Raise	Sector Perform	$43→$46
Jul 7, 2026	Truist Securities	Gregory Renza	PT Raise	Hold	$54→$56
Jul 2, 2026	UBS	Ashwani Verma	PT Raise	Neutral	$43→$52
Jul 2, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$56
Jun 25, 2026	Truist Securities	Gregory Renza	Downgrade	Buy→Hold	$51→$54
Jun 24, 2026	Citizens	Silvan Turkcan	PT Raise	Market Outperform	$50→$55
May 7, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$54→$56
May 6, 2026	TD Cowen	Yaron Werber	PT Raise	Buy	$51→$55
May 6, 2026	Morgan Stanley	Sean Laaman	PT Raise	Equal-Weight	$49→$50
May 6, 2026	Stifel	Stephen Willey	PT Raise	Hold	$44→$47
May 6, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Equal-Weight	$35→$40

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Sector Perform on Exelixis, Raises Price Target to $51

RBC Capital analyst Leonid Timashev maintains Exelixis (NASDAQ:EXEL) with a Sector Perform and raises the price target from $45 to $51.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Exelixis, Lowers Price Target to $45

RBC Capital analyst Leonid Timashev maintains Exelixis (NASDAQ:EXEL) with a Sector Perform and lowers the price target from $46 to $45.

Benzinga Newsdesk

Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In

FDA extends Exelixis NDA review for zanzalintinib to March 2027. Analyst evaluates stock volatility and revenue outlook.

Vandana Singh

PRO
BMO Capital Initiates Coverage On Exelixis with Market Perform Rating, Announces Price Target of $54

BMO Capital analyst David Lebowitz initiates coverage on Exelixis (NASDAQ:EXEL) with a Market Perform rating and announces Price Target of $54.

Benzinga Newsdesk

PRO
Truist Securities Maintains Hold on Exelixis, Lowers Price Target to $52

Truist Securities analyst Gregory Renza maintains Exelixis (NASDAQ:EXEL) with a Hold and lowers the price target from $56 to $52.

Benzinga Newsdesk

PRO
Stifel Maintains Hold on Exelixis, Raises Price Target to $51

Stifel analyst Stephen Willey maintains Exelixis (NASDAQ:EXEL) with a Hold and raises the price target from $47 to $51.

Benzinga Newsdesk